A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
Am J Psychiatry
; 164(1): 160-2, 2007 Jan.
Article
em En
| MEDLINE
| ID: mdl-17202560
ABSTRACT
OBJECTIVE:
Problems related to illegal amphetamine use have become a major public health issue in many developed countries. To date, evidence on the effectiveness of psychosocial treatments has remained modest, and no pharmacotherapy has proven effective for amphetamine dependence.METHOD:
Individuals meeting DSM-IV criteria for intravenous amphetamine dependence (N=53) were randomly assigned to receive aripiprazole (15 mg/day), slow-release methylphenidate (54 mg/day), or placebo for 20 weeks. The study was terminated prematurely due to unexpected results of interim analysis. An intention-to-treat analysis was used. The primary outcome measure was the proportion of amphetamine-positive urine samples.RESULTS:
Patients allocated to aripiprazole had significantly more amphetamine-positive urine samples than patients in the placebo group (odds ratio=3.77, 95% CI=1.55-9.18), whereas patients who received methylphenidate had significantly fewer amphetamine-positive urine samples than patients who had received placebo (odds ratio=0.46, 95% CI=0.26-0.81).CONCLUSIONS:
Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe amphetamine dependence.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Abuso de Substâncias por Via Intravenosa
/
Quinolonas
/
Transtornos Relacionados ao Uso de Anfetaminas
/
Metilfenidato
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article